European S2k Guideline on Chronic Pruritus

Vol 99, Issue 5, 469-506, 2019

Elke Weisshaar, Jacek C. Szepietowski, Florence J. Dalgard, Simone Garcovich, Uwe Gieler, Ana M. Giménez-Arnau, Julien Lambert, Tabi Leslie, Thomas Mettang, Laurent Misery, Ekin Şavk, Markus Streit, Erwin Tschachler, Erwin Tschachler, Joanna Wallengren, Sonja Ständer
DOI: 10.2340/00015555-3164 

Abstract

Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases chronic pruritus may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of chronic pruritus comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating chronic pruritus needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. We present the updated and consensus based (S2k) European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org).

Full Text HTML   -     PDF

Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens

Pall, Brian, OD, MS*; Gomes, Paul, MS†; Yi, Frank, MS*; Torkildsen, Gail, MD‡

Cornea: March 19, 2019 - Volume Publish Ahead of Print - Issue - p

doi: 10.1097/ICO.0000000000001911

Clinical Science: PDF Only

OPEN

SDC

PAP

• Abstract
• 
  

Purpose: A contact lens (CL)-based drug delivery system for therapeutic delivery of the antihistamine ketotifen was tested in 2 parallel, conjunctival allergen challenge-based trials.

Severe anaphylaxis after pelvic examination: a case report of dual latex and chlorhexidine allergies

Allergy, Asthma & Clinical Immunology
 
• Case report
• Open Access

• Mongkhon SompornrattanaphanEmail author,
• Piyawut Kreetapirom,
• Yuttana Srinoulprasert,
• Duangjit Kanistanon,
• Anchalika Klinniyom,
• Chamard Wongsa and
• Torpong Thongngarm

Allergy, Asthma & Clinical Immunology201915:19

https://doi.org/10.1186/s13223-019-0335-4

Abstract

Background

Natural rubber latex and chlorhexidine have previously been identified as causative substances in perioperative anaphylaxis. A pelvic examinations is generally considered noninvasive, however, this procedure is rarely associated with severe allergic reactions.

World Allergy Congress Lyon 2019 : Novel therapies in skin allergic diseases.

FOCUS ON OUR PLENARY SESSIONS

“Novel therapies in skin allergic diseases”   Atopic dermatitis (AD) is the most prevalent skin allergy. Not surprisingly, there has been increasing interest in developing experimental approaches to study the pathogenesis of human AD in vivo, in vitro, and in silico to better define pathophysiologic mechanisms and identify novel therapeutic targets and biomarkers that predict therapeutic response.

Physician Confidence in Artificial Intelligence: An Online Mobile Survey

Original Paper

• Songhee Oh¹, MD ; 
• Jae Heon Kim², MD ; 
• Sung-Woo Choi³, MD ; 
• Hee Jeong Lee¹, MD ; 
• Jungrak Hong⁴, MD ; 
• Soon Hyo Kwon¹, MD 

¹Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea

²Department of Urology, Soonchunhyang University Hospital, Seoul, Republic of Korea

³Department of Orthopedic Surgery, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea

⁴Department of Internal Medicine, New York Medical College, New York Health Hospital, New York, NY, United States

ABSTRACT

Background: It is expected that artificial intelligence (AI) will be used extensively in the medical field in the future.

Objective: The purpose of this study is to investigate the awareness of AI among Korean doctors and to assess physicians’ attitudes toward the medical application of AI.

The Allergic Rhinitis Control Test Questionnaire Is Valuable in Guiding Step-Down Pharmacotherapy Treatment of Allergic Rhinitis

The Journal of Allergy and Clinical Immunology: In Practice

Volume 7, Issue 1, January 2019, Pages 272-278

Background
Allergic Rhinitis Control Test (ARCT) has been validated in the allergic rhinitis (AR) step-up pharmacotherapy management approach.
Objective
The aim of our study was to evaluate the potential of ARCT in AR step-down pharmacotherapy.

A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults

• Research article
• Open Access
• Open Peer Review

BMC Pulmonary Medicine

• Jørgen G. BramnessEmail author and
• Tilmann von Soest

BMC Pulmonary Medicine201919:52

https://doi.org/10.1186/s12890-019-0814-x

Open Peer Review reports

Abstract

Background

A small number of studies have shown that the use of cannabis increases the risk of bronchial asthma. There is, however, a paucity of longitudinal studies which are able to control for known risk factors of bronchial asthma.

Comparison of therapeutic effects of inhaled corticosteroids on three subtypes of cough variant asthma as classified by the impulse oscillometry system

• Research
• Open Access
• 
  

Respiratory Research

• Hiroyuki Sugawara,
• Atsushi SaitoEmail authorView ORCID ID profile,
• Saori Yokoyama,
• Kazunori Tsunematsu and
• Hiroki Takahashi

Respiratory Research201920:41

https://doi.org/10.1186/s12931-019-1005-2

Abstract

Background

Cough variant asthma (CVA) is one of the most common causes of chronic persistent cough, and early treatment with inhaled corticosteroids (ICSs) is recommended to attenuate the inflammation and remodeling.